Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer
- Conditions
- Cervical Cancer
- Interventions
- Registration Number
- NCT02635360
- Lead Sponsor
- Linda R Duska
- Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or during chemoradiation.
- Detailed Description
Primary: (1) To estimate the immunologic effects, as assessed in the tumor \& PBMC, of both sequential and concurrent administration of pembrolizumab to CRT. Change between pre and post measurements of HPV E2, E7 specific CD8+ T cells, regulatory FoxP3+ T cells (Tregs) and the ratio of CD8+ T cells to Tregs are the immune measurements of primary interest. (2) To determine the safety of concurrent chemoradiation in combination with pembrolizumab for the treatment of locally advanced cervical cancer. Secondary: (1) To estimate rates of complete metabolic response on PET/CT imaging obtained 12 weeks after CRT.
(2) To estimate rates of distant metastasis as the first site of recurrence for patients.
(3) To estimate the influence of concurrent and consolidative MK-3475 on levels of plasminogen activator inhibitor-1 (PAI-1), a marker of immunosuppressive TGF-B.
(4) To estimate the influence of concurrent and consolidative MK-3475 on levels of IDO, an enzyme that depletes tryptophan, which is essential for T-cell function.
(5) To estimate the influence of concurrent and consolidative MK-3475 on levels of MHC class I (CD8+ T cell ligand) and MICA (NK ligand), as measured by MHC.
(6) To estimate the progression free survival (PFS) in subjects with locally advanced cervical cancer treated with sequential and concurrent administration of pembrolizumab in relation to CRT.
(7) To estimate the overall survival (OS) in subjects with locally advanced cervical cancer treated with sequential and concurrent administration of pembrolizumab in relation to CRT.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 88
- Confirmed cervical cancer.
- Must have adequate organ function.
- Subject is pregnant.
- Recurrent cervical cancer.
- Distant metastases.
- Malignancy within the last 5 years; basal cell carcinoma or squamous cell carcinoma of the skin that has undergone potentially curative therapy is permissable.
- Subject has had prior radiation, chemotherapy, targeted therapy, or investigational therapy for cervical cancer.
- Subject has a immunodeficiency.
- Known history of HIV, Hepatitis B, Hepatitis C, TB, or inflammatory bowel disease.
- Hypersensitivity to pembrolizumab or similar drugs.
- Subject has an active autoimmune disease in the past 2 years.
- Known history of non-infectious pneumonitis.
- Subject has an active infection.
- Subject has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases are permissible. Talk to Study Contact for specifics.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Following chemoradiation Brachytherapy Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. After chemoradiation is complete, subjects will receive the study drug, pembrolizumab. Concurrent to chemoradiation Brachytherapy Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. While subjects are receiving chemotherapy and radiation, they will also receive the study drug, pembrolizumab. Concurrent to chemoradiation Cisplatin Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. While subjects are receiving chemotherapy and radiation, they will also receive the study drug, pembrolizumab. Following chemoradiation Pembrolizumab Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. After chemoradiation is complete, subjects will receive the study drug, pembrolizumab. Concurrent to chemoradiation Pembrolizumab Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. While subjects are receiving chemotherapy and radiation, they will also receive the study drug, pembrolizumab. Following chemoradiation Cisplatin Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. After chemoradiation is complete, subjects will receive the study drug, pembrolizumab.
- Primary Outcome Measures
Name Time Method Change in immunologic markers following combination of study drug with chemoradiation At 6 weeks of chemoradiation and 12 weeks post-chemoradiation Expression of immune markers measured at pre and post administration of study drug with chemoradiation will be compared.
Incidence of dose limiting toxicities From start of treatment until 12 weeks post-chemoradiation
- Secondary Outcome Measures
Name Time Method Metabolic Response Rate on PET/CT imaging 12 weeks after chemotherapy Overall Survival From start of treatment until up to 5 years following end of treatment Progression Free Survival From start of treatment until up to 5 years following end of treatment Incidence of distant metastases From start of treatment until up to 5 years following end of treatment
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (8)
Washington University, School of Medicine
🇺🇸Saint Louis, Missouri, United States
Levine Cancer Institute
🇺🇸Charlotte, North Carolina, United States
INOVA Fairfax Hospital
🇺🇸Falls Church, Virginia, United States
University of South Alabama Mitchell Cancer Institute
🇺🇸Mobile, Alabama, United States
Johns Hopkins
🇺🇸Baltimore, Maryland, United States
Virginia Commonwealth University
🇺🇸Richmond, Virginia, United States
University of Virginia
🇺🇸Charlottesville, Virginia, United States
University of Oklahoma
🇺🇸Oklahoma City, Oklahoma, United States